Related Experiment Video
Updated: Jan 22, 2026

Murine Corneal Transplantation: A Model to Study the Most Common Form of Solid Organ Transplantation
Published on: November 17, 2014
Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review
Juliya Fisher1, Nathalie Zeitouni2, Weijia Fan3
1Department of Dermatology, Columbia University Irving Medical Center, New York, New York.
Background:
The use of immunotherapies in the treatment of metastatic cancers has significantly advanced oncology. However, due to safety concerns, solid organ transplant recipients (SOTRs) are routinely excluded from immunotherapy trials; thus, there is limited data for these agents in this population.
Methods:
A systematic review was performed to evaluate the safety and efficacy of immunotherapies in SOTRs with metastatic cancers. Fisher's exact test and Kruskal-Wallis test were used for analysis.
Results:
In total, 37% of patients experienced organ rejection, and 14% died as a result of graft rejection. Nivolumab was associated with the highest rejection rate (52.2%), followed by pembrolizumab (26.7%) and ipilimumab (25%; P = .1774). The highest rejection rate was seen in patients with kidney transplants (40.1%), then liver (35%) and heart (20%) transplants (P = .775), and 64% of patients succumbed to the progression of malignancy. For all cases, rates of progression or death secondary to disease were highest for ipilimumab (75%), followed by nivolumab (43%) and pembrolizumab (40%; P = .1892). The overall response rate was highest for pembrolizumab (40%), followed by nivolumab (30%) and ipilimumab (25%; P = .7929).
Limitations:
The small sample size.
Conclusion:
Physicians must be cautious when administering immunotherapy to SOTRs. However, rejection is not the most common cause for death in this population.
Insights
Immunotherapy use in solid organ transplant recipients (SOTRs) with metastatic cancer shows significant risks of organ rejection. Despite cautious use, cancer progression remains a more frequent cause of death than graft rejection in this population.
Area of Science:
- Oncology
- Transplant Immunology
Background:
- Immunotherapies have advanced cancer treatment.
- Solid organ transplant recipients (SOTRs) are typically excluded from immunotherapy trials.
- Limited data exists on immunotherapy safety and efficacy in SOTRs with metastatic cancers.
Purpose of the Study:
- To systematically review the safety and efficacy of immunotherapies in SOTRs with metastatic cancers.
- To analyze organ rejection rates and mortality causes in SOTRs receiving immunotherapy.
Main Methods:
- Systematic review of existing literature.
- Statistical analysis using Fisher's exact test and Kruskal-Wallis test.
Main Results:
- 37% of SOTRs experienced organ rejection; 14% died from rejection.
- Nivolumab had the highest rejection rate (52.2%), followed by pembrolizumab (26.7%) and ipilimumab (25%).
- Kidney transplant recipients showed the highest rejection rates (40.1%). Cancer progression caused death in 64% of patients, with ipilimumab associated with the highest disease-related mortality (75%). Pembrolizumab demonstrated the highest overall response rate (40%).
Conclusions:
- Physicians should exercise caution when administering immunotherapy to SOTRs.
- While organ rejection is a concern, it is not the most common cause of death in this patient group.
- Further research with larger sample sizes is needed to fully understand immunotherapy outcomes in SOTRs.
Related Concept Videos
Patient-centered Care
The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
Lattice Centering and Coordination Number
Types of Unit Cells
Imagine taking a large number of identical...
Metallic Solids
All metallic solids exhibit high thermal and electrical conductivity, metallic luster, and malleability....
Structures of Solids
Review and Preview
Percentiles are a type of fractile that partition data into...

